The firm has launched a yearly subscription program that includes quarterly blood tests to look for genetic and proteomic signs of metastasis or cancer recurrence.
The firm announced a 14 percent drop year-over-year in fourth quarter revenues and plans to reduce personnel and other costs to support development of a precision drug it has licensed.
The company believes Indian clinicians and patients will be receptive to this new technology, but only in an efficient and actionable form.
Using multiple samples from more than 60,000 individuals at a participating hospital, the firm tracks circulating molecules over time in relation to cancer.
The approach, dubbed ThromboSeq, enables clinical researchers to identify different cancer types by looking at tumor-educated, platelet-derived RNA using RNA-seq.
The Seattle-based firm plans to partner with pharma and biotech to use its duplex sequencing technology in applications such as oncology and forensics.
Natera discussed its plans to move into the whole-genome newborn screening market and provided updates on its NIPT and oncology businesses.
Natera saw total Q4 2016 revenues decline to $49.3 million, despite an increase in testing volumes.
Researchers showed in a new study that patterns of methylation co-occuring at different sites could help distinguish cancer DNA in the blood, and mark its original source in body.
The company said it accessioned 1,175 total samples during the quarter, up from 663 total samples in Q4 2015.
Harold Varmus, a former NIH director, says that proposed reductions to the agency's budget are worrisome.
The Genome 10K project is to sequence about 10,000 vertebrate genomes, including ones of endangered species, Digital Trends reports.
The new Coalition to Save NIH Funding aims to educate lawmakers and the public on the significance of biomedical research.
In PLOS this week: analysis of viral sequences from human blood samples, gut microbiomes of heart failure patients, and more.